The NCI Clinical Trials and Translational Research Advisory Committee has approved an interim set of guidelines for streamlining requirements for conduct of clinical trials.
NCI will immediately start the process of streamlining IND-exempt trials in order to make them faster, simpler, more flexible, less expensive, and easier to integrate with clinical practice, James Doroshow, NCI deputy director for clinical and translational research and director of the Division of Cancer Treatment and Diagnosis, said to The Cancer Letter. On Nov. […]
It’s time to supercharge NCI’s role in redefining clinical trials and in strengthening the cancer research enterprise, NCI Director Monica Bertagnolli said Nov. 9 in her first director’s report.
